HUMANIZED ANTI-EPIREGULIN ANTIBODY, AND CANCER THERAPEUTIC AGENT COMPRISING SAID ANTIBODY AS ACTIVE INGREDIENT

• Main Authors: HASHIMOTO ERI, KURAMOCHI TAICHI, TAKEIRI ETSUKO, IGAWA TOMOYUKI, TSUNODA HIROYUKI, ESAKI KEIKO, SUZUKI MASAMI, WATANABE YOSHINORI, MAEDA ATSUHIKO, TAMBA SHIGERO, KATO ATSUHIKO, TACHIBANA TATSUHIKO, SHIRAIWA HIROTAKE, KINOSHITA YASUKO
• Format: Patent
• Language: English; Korean
• Published: 04.09.2014
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The inventors successfully produced anti-Epiregulin antibodies showing cross-species reactivity between cynomolgus monkey (non-human animals) and human, anti-Epiregulin antibodies with suppressed chemical degradation, anti-Epiregulin antibodies with lowered isoelectric point, anti-Epiregulin antibodies with increased thermal denaturation midpoint temperature, and anti-Epiregulin antibodies with reduced amount of aggregate by performing appropriate amino acid residue substitutions in the variable-region sequences of the humanized EP27 antibody which inhibits growth of cancer cells by exhibiting cytotoxic activity and neutralizing activity against anti-human Epiregulin-expressing cancer cells.